ArticleCancers2024

The Impact of FDA-Approved Novel Agents for Steroid-Refractory Chronic Graft vs. Host Disease on Treatment Patterns and Outcomes-A Single-Center Longitudinal Cohort Analysis.

Gil Fridberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.